Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Microglial Phagocytosis of Newborn Cells Is Induced by Endocannabinoids and Sculpts Sex Differences in Juvenile Rat Social Play.

VanRyzin JW, Marquardt AE, Argue KJ, Vecchiarelli HA, Ashton SE, Arambula SE, Hill MN, McCarthy MM.

Neuron. 2019 Apr 17;102(2):435-449.e6. doi: 10.1016/j.neuron.2019.02.006. Epub 2019 Feb 28.


Sex and seasonal differences in mRNA expression of estrogen receptor ╬▒ (ESR1) in red-sided garter snakes (Thamnophis sirtalis parietalis).

Ashton SE, Vernasco BJ, Moore IT, Parker MR.

Gen Comp Endocrinol. 2018 Oct 1;267:59-65. doi: 10.1016/j.ygcen.2018.05.026. Epub 2018 May 25.


End of life care: The experiences of advance care planning amongst family caregivers of people with advanced dementia - A qualitative study.

Ashton SE, Roe B, Jack B, McClelland B.

Dementia (London). 2016 Sep;15(5):958-75. doi: 10.1177/1471301214548521. Epub 2014 Sep 3.


AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.


Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, J├╝rgensmeier JM, Womack C.

Clin Cancer Res. 2010 Jul 15;16(14):3548-61. doi: 10.1158/1078-0432.CCR-09-2797. Epub 2010 Jul 6.


Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.

Fens MH, Hill KJ, Issa J, Ashton SE, Westwood FR, Blakey DC, Storm G, Ryan AJ, Schiffelers RM.

Br J Cancer. 2008 Oct 21;99(8):1256-64. doi: 10.1038/sj.bjc.6604675. Epub 2008 Sep 16.


Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.

Gould S, Westwood FR, Curwen JO, Ashton SE, Roberts DW, Lovick SC, Ryan AJ.

J Natl Cancer Inst. 2007 Nov 21;99(22):1724-8. Epub 2007 Nov 13.


Haemolytic uraemic syndrome associated with a family cluster of enterohaemorrhagic Escherichia coli.

Hanna JN, Humphreys JL, Ashton SE, Murphy DM.

Commun Dis Intell Q Rep. 2007 Sep;31(3):300-3. No abstract available.


Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.

Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, Ryan AJ.

Neoplasia. 2007 May;9(5):382-91.


Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.

Cullis ER, Kalber TL, Ashton SE, Cartwright JE, Griffiths JR, Ryan AJ, Robinson SP.

Microvasc Res. 2006 Mar;71(2):76-84. Epub 2006 Mar 10.


Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.

Reigan P, Edwards PN, Gbaj A, Cole C, Barry ST, Page KM, Ashton SE, Luke RW, Douglas KT, Stratford IJ, Jaffar M, Bryce RA, Freeman S.

J Med Chem. 2005 Jan 27;48(2):392-402.


Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.

Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, Waterton JC.

Br J Cancer. 2003 May 19;88(10):1592-7.


ZD6126: a novel small molecule vascular targeting agent.

Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1497-502.


ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH.

Cancer Res. 2002 Oct 15;62(20):5749-54.


Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ.

Clin Cancer Res. 2002 Jun;8(6):1974-83.


Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L.

Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4.


Phenylethylaminergic mechanisms in attention-deficit disorder.

Baker GB, Bornstein RA, Rouget AC, Ashton SE, van Muyden JC, Coutts RT.

Biol Psychiatry. 1991 Jan 1;29(1):15-22.


Supplemental Content

Loading ...
Support Center